LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Status:
Completed
Trial end date:
2019-12-06
Target enrollment:
Participant gender:
Summary
ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma
of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more
thoroughly in the subgroup of patients who had the best response in prior studies as well as
determine whether there are any biomarkers which can predict for response.